Milford, Massachusetts (MMD Newswire) May 15, 2009 -- Avecia Biotechnology Inc and Giuliani S.p.A. have entered into a long term agreement for the process development and manufacture by Avecia of clinical and commercial quantities of GED-0301; Giuliani's first Oligonucleotide based therapeutic which is in clinical trials for the treatment of Crohn's Disease.

"The basis of our strategy in drug development is to assemble the best team of experts for each program and since GED-0301 is an oligonucleotide we are very pleased that Avecia as market leader in this space has joined our team", said Dr. Germano Giuliani, CEO and President of Giuliani S.p.A. GED-0301 is the first oral administered tabletized oligonucleotide therapeutic entering clinical trials in Europe. Detlef Rethage, President Avecia Biotechnology Inc, commented "Avecia is proud to be selected as process development and long term manufacturing partner for GED-0301. We intend to deliver to Giuliani the full benefit of our track record of successful process validations and regulatory inspection."

About Avecia

Avecia Biotechnology Inc. is a drug development and manufacturing service company located in Milford, MA. The company is a recognized leader in process development; manufacturing and related services for DNA and RNA based therapeutics. Avecia provides major pharmaceutical and biotech companies with the most experienced team in its industry and successfully passed several FDA inspections without 483's. Avecia offers services from the very first gram for preclinical testing to post commercial launch of innovative DNA and RNA based therapeutics. For additional information, please visit: www.aveciabiotech.com

About Giuliani

Giuliani S.p.A., an Italian privately owned pharmaceutical company, targets specialty markets with patented and innovative products that focused on meeting the needs of the specialist physician. It focuses on the development of new therapeutic agents for the treatment and management of Inflammatory Bowel Diseases, Dermatological and Metabolic Disorders.

###

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.